Last reviewed · How we verify

NCT05353556

Effects of Home-based Inspiratory Muscle Training in Patients With IPF

Completed NA Last updated 10 January 2024
What this trial tests

NA trial testing Inspiratory Muscle Training (IMT) in Idiopathic Pulmonary Fibrosis in 28 participants. Completed in 30 May 2022.

Timeline
21 February 2022
Primary endpoint
25 April 2022
30 May 2022

Quick facts

Lead sponsorDokuz Eylul University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment28
Start date21 February 2022
Primary completion25 April 2022
Estimated completion30 May 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Dokuz Eylul University

Who can join

Adults 40 to 75, any sex, with Idiopathic Pulmonary Fibrosis or IPF. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the effects of the home-based inspiratory muscle training program on lung functions, dyspnea, inspiratory muscle strength, functional capacity and quality of life in patients with idiopathic pulmonary fibrosis. Patients are evaluated before the inspiratory muscle training and after 8 weeks of training.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Inspiratory Muscle Training (IMT)

Trials testing the same drug.

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

Other Dokuz Eylul University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05353556.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing